Royalty Pharma plc - Ordinary Shares - Class A Stock, NASDAQ:RPRX
110 East 59th Street, 33rd floor, New York, New York 10022
United States of America
Number of Employees: 75
Royalty Pharma Plc provides drug development services. It operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio includes royalties, including AbbVie and J&JÃ¢â?¬â?¢s Imbruvica, Astellas and PfizerÃ¢â?¬â?¢s Xtandi, BiogenÃ¢â?¬â?¢s Tysabri, GileadÃ¢â?¬â?¢s HIV franchise, MerckÃ¢â?¬â?¢s Januvia, NovartisÃ¢â?¬â?¢ Promacta, VertexÃ¢â?¬â?¢s Kalydeco, Orkambi, Symdeko and Trikafta, and five development-stage product candidates. The company was founded by Pablo Gerardo Legorreta and Rory B. Riggs in 1996 and is headquartered in New York, NY.